Cochrane · systematic review · CD002996
Inhaled hyperosmolar agents for bronchiectasis
Hart, A, Sugumar, K, Milan, SJ, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
8
No studies
1
Included studies
NR
No studies 1 · 7.1%Ungraded 5 · 35.7%Very low 0 · 0%Low 0 · 0%Moderate 8 · 57.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Inhaled mannitol versus placebo for bronchiectasis
Population: patients with bronchiectasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbations Exacerbation rate per year. Inhaled mannitol vs placebo | RR 0.92 [0.78, 1.08] | 1 study · 461 participants | Moderate Downgraded: risk of bias |
Hospitalisations Number of participants experiencing one of more hospitalisations. Inhaled mannitol vs placebo | RR 0.61 [0.34, 1.09] | 1 study · 461 participants | Moderate Downgraded: risk of bias |
Adverse events Inhaled mannitol vs placebo | OR 0.96 [0.61, 1.51] | 2 studies · 804 participants | Moderate Downgraded: risk of bias, inconsistency |
Mortality Inhaled mannitol vs placebo | no estimate extracted | NR | No studies |
Health‐related quality of life measured on the SGRQ Scale from 0 to 100. Low on the scale is better. Inhaled mannitol vs placebo | no estimate extracted | 3 studies · 840 participants | Moderate Downgraded: risk of bias, inconsistency |
Symptoms Bronchiectasis Symptoms Questionnaire Inhaled mannitol vs placebo | no estimate extracted | 1 study · 343 participants | Moderate Downgraded: risk of bias, inconsistency |
Lung function FEV1 (L) Inhaled mannitol vs placebo | MD 0.03 | 1 study · 343 participants | Moderate Downgraded: risk of bias, inconsistency |
Hypertonic saline versus isotonic saline for bronchiectasis
Population: patients with bronchiectasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency and duration of exacerbations Hypertonic saline vs isotonic saline | no estimate extracted | 2 studies · 70 participants | Ungraded |
Hospitalisations Hypertonic saline vs isotonic saline | no estimate extracted | 1 study · 40 participants | Ungraded |
Adverse events Hypertonic saline vs isotonic saline | OR 8.2 [0.4, 169.9] | 1 study · 40 participants | Ungraded |
Mortality Hypertonic saline vs isotonic saline | no estimate extracted | 4 studies · 113 participants | Ungraded |
Symptoms: cough, sputum volume and ease of expectoration, wheeze, dyspnoea Hypertonic saline vs isotonic saline | no estimate extracted | 4 studies · 113 participants | Ungraded |
Lung function FEV1 (L) Hypertonic saline vs isotonic saline | no estimate extracted | 1 study · 40 participants | Moderate Downgraded: imprecision |
Health‐related quality of life. Measured on the SGRQ (total score reported) Hypertonic saline vs isotonic saline | no estimate extracted | 1 study · 40 participants | Moderate Downgraded: imprecision |